t
Life Science REIT plc announced on 24 June 2022 that non-executive Director Richard Howell will assume the role of Senior Independent Director. The Company also confirmed his appointment as Chair of the Audit and Risk Committee, which was previously announced on 3 May 2022, with both roles effective from 24 June 2022.
| Date | 24 Jun 2022 |
| Time | 12:58:47 |
| Category | Board changes |
| ID | 1578Q |
24 June 2022
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Changes to Board Roles
Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that Richard Howell, currently a non-executive Director of the Company, will take on the role of Senior Independent Director. The Company also confirms his appointment, further to the announcement on 3 May 2022, as Chair of the Audit and Risk Committee.
Both appointments are with effect from today. Richard Howell's biography is available on the Company's website at www.lifesciencereit.co.uk/about-us/board-of-directors/.
Enquiries:
|
Link Company Matters Limited - Company Secretary |
|
|
|
|
|
|
|
|
Ironstone Asset Management - Investment Adviser |
|
|
Simon Farnsworth |
via Buchanan below |
|
|
|
|
Panmure Gordon (UK) Limited - Nominated Adviser and Joint Corporate Broker |
+44 20 7886 2500 |
|
Atholl Tweedie / Sapna Shah / Philip Shields / Chloe Ponsonby |
|
|
|
|
|
Jefferies International Limited - Joint Corporate Broker |
+44 20 7029 8000 |
|
Tom Yeadon / Andrew Morris / Oliver Nott |
|
|
|
|
|
Buchanan - Financial PR |
+44 20 7466 5000 |
|
Mark Court / Henry Wilson / Verity Parker |
|
|
|
Notes to editors
Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector.
The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to occupiers operating in the life science sector in the UK.
Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk